Summary
PRA Health Sciences was selected to conduct a global program of studies that targeted 2,200+ patients with multiple sclerosis (MS). Although there were many challenges, the study team implemented a comprehensive risk-management plan that resulted in achieved recruitment goals and positioned the sponsor as a “Sponsor of Choice” in MS research.
Register to download
Program Challenges Strengthen Partnership
You may also be interested in:
Poster
Marijuana Effect on Differentiating an Opioid from Placebo During the Discrimination Phase of a Human Abuse Potential Study
Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP…
Poster
Pharmacokinetic Charcateristic of Oral_Intranasal Morphine ARER
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral…
White Paper
PRA Insights Report: Alzheimer's Disease Research
This PRA Insights report focusing on Alzheimer’s disease research was compiled from survey data gathered at the 2017 Alzheimer’s Association…